C. Schulz

发表

Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy

W. Winkelmann, N. Willich, Michael Thomas, 2012, Cancer Chemotherapy and Pharmacology.

Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation.

G. Rogler, E. Holler, R. Andreesen, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study

M. Hjermstad, A. Bottomley, M. Koller, 2020, Journal of thoracic disease.

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.

U. Dührsen, S. Koschmieder, W. Berdel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Psychosocial Burden and Quality of Life of Lung Cancer Patients: Results of the EORTC QLQ-C30/QLQ-LC29 Questionnaire and Hornheide Screening Instrument

M. Koller, C. Schulz, M. Koch, 2021, Cancer management and research.

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol fo

N. Reinmuth, F. Klauschen, C. Belka, 2021, Translational lung cancer research.

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

R. Riedel, L. Heukamp, P. Christopoulos, 2021, Therapeutic advances in medical oncology.

Gender Differences in Quality of Life of Metastatic Lung Cancer Patients

Arno Mohr, K. Müller, C. Schulz, 2022, Cancer management and research.

Gender Differences in Quality of Life of Metastatic Lung Cancer Patients

Arno Mohr, K. Müller, C. Schulz, 2022 .

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.

D. Kazdal, J. Budczies, M. Kirchner, 2022, European journal of cancer.

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

J. Ficker, A. Hartmann, R. Stoehr, 2013, British Journal of Cancer.

Immunomodulation by IFN-γ in patients with resistant infections and accompanying bronchiolitis obliterans following allo-SCT

E. Holler, R. Andreesen, D. Wolff, 2011, Bone Marrow Transplantation.

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

G. Bouche, T. Pukrop, P. Staib, 2021, Frontiers in Pharmacology.

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

M. Hjermstad, A. Bottomley, M. Koller, 2015, Cancer.

An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients

M. Hjermstad, A. Bottomley, M. Koller, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

S. Haferkamp, K. Drexler, D. Calvisi, 2022, British Journal of Cancer.

The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation

E. Holler, D. Wolff, G. Hildebrandt, 2016, Croatian medical journal.

An international field study to investigate the psychometric properties of the updated EORTC QLQ-LC29 module for assessing quality of life in patients with lung cancer

M. Hjermstad, A. Bottomley, W. Chie, 2021 .

Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.

M. Hjermstad, A. Bottomley, M. Koller, 2020, The Lancet. Oncology.

Impact of gastric cancer treatment on quality of life of patients.

K. Schütte, C. Schulz, Kristina Middelberg-Bisping, 2021, Best practice & research. Clinical gastroenterology.

Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.

C. Watkins, D. Gandara, R. Rosenthal, 2019, Clinical lung cancer.

Gender Differences in Symptom Burden, Functional Performance and Global Quality of Life of Lung Cancer Patients Receiving Inpatient versus Outpatient Treatment

J. Braess, K. Müller, C. Schulz, 2023, Cancer management and research.

Interventional radiotherapy (brachytherapy) achieves very good long‐term quality of life in children and adolescents with soft‐tissue sarcoma

A. Claviez, G. Kovács, M. Lauten, 2020, Pediatric blood & cancer.

LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

L. T. Anh, A. Szczesna, K. Prabhash, 2022, Annals of Oncology.

1418TiP Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008

T. Owonikoko, A. Cardona, J. Penrod, 2020 .

Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

T. Owonikoko, J. Gray, T. Kato, 2020 .

An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.

M. Hjermstad, A. Bottomley, M. Koller, 2017 .

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

F. Cappuzzo, A. Szczesna, H. K. Vollan, 2023, The Lancet.

NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation.

G. Rogler, E. Holler, R. Andreesen, 2005 .

IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen

F. Cappuzzo, A. Szczesna, Geoffrey Liu, 2022, Social Science Research Network.